Cognition Therapeutics, Inc. provided consolidated earnings guidance for the year ended December 31, 2023. For the year, the company expected net loss to be approximately $25.6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | -1.36% |
|
+11.28% | +17.30% |
Jun. 07 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
May. 29 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.30% | 86.93M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023